[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content
Springer Nature Link
Log in

A new once-a-day fentanyl citrate patch (Fentos® Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The recommended dosing interval for transdermal fentanyl is every 72 h. However, some patients will have “end-of-dose failure,” which may be seen as an increase of episodes of severe pain flares at the third day after application of the patch. A new once-a-day fentanyl patch was developed in Japan since 2010. This study aimed to assess the efficacy of the once-a-day fentanyl citrate patch for patients with cancer-related pain receiving the 72-h transdermal fentanyl not lasting 72 h.

Methods

We performed a cross-sectional retrospective analysis of 445 inpatients with the 72-h transdermal fentanyl at Higashi Sapporo Hospital. We could switch to the once-a-day fentanyl citrate patch if patients reported inadequate pain relief beyond 48 h after application of the 72-h transdermal fentanyl. Patients recorded baseline scores for background pain intensity (PI) and the frequency of use of daily rescue medication for breakthrough cancer pain (BTcP).

Results

Of all patients, 10.1 % showed the increase in PI of 30 % or more baseline PI on the third day after application of the 72-h transdermal fentanyl. Of patients, 84.4 % were converted from equivalent dose of the 72-h transdermal fentanyl to the once-a-day fentanyl citrate patch. On the third day after switching, 60.5 % of patients showed a reduction of more than 30 % from baseline PI. Switching to the once-a-day fentanyl citrate patch significantly reduced the mean frequency of daily rescue dose for BTcP.

Conclusions

A once-a-day fentanyl citrate patch provided stable pain control. Its use may be considered as the dominant strategy for patients receiving a 72-h transdermal fentanyl not lasting 72 h.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Muijsers RBR, Wagstaff AJ (2001) Transdermal fentanyl: an update review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61(15):2289–2307

    Article  CAS  PubMed  Google Scholar 

  2. Payne R (1998) Factors influencing quality of life in cancer patients; the role of transdermal fentanyl in the management of pain. Semin Oncol 25(3 Suppl 7):47–53

    CAS  PubMed  Google Scholar 

  3. Marier JF, Lor M, Potvin D et al (2006) Pharmacokinetics, tolerability and performances of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 46(6):642–653

    Article  CAS  PubMed  Google Scholar 

  4. US Food and Drug Administration. Information for healthcare professionals: Fentanyl Transdermal System (marketed as Duragesic and generics) (2007) http://www.accessdata.fda.gov/drugsatfda_docs/…/19813s039lbl.pdf Accessed 3 May 2015

  5. Zeppetella G (2011) Breakthrough pain in cancer patients. Clin Oncol 23:393–398

    Article  CAS  Google Scholar 

  6. Takakuwa O, Oguri T, Maeno K et al (2013) Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer. Am J Hosp Palliat Care 30(7):726–729

    Article  PubMed  Google Scholar 

  7. Caraceni A, Bertetto O, Labianca R et al (2012) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manage 43(5):833–841

    Article  PubMed  Google Scholar 

  8. Farrar JT, Young JP Jr, LaMoreaux L et al (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158

    Article  CAS  PubMed  Google Scholar 

  9. Hall LM, O’lenic K (2012) Treatment strategies to overcome and end-of-dose failure with oral and transdermal opioids. J Pharm Pract 25:503–509

    Article  PubMed  Google Scholar 

  10. FENTOS® TAPE (once-a-day fentanyl citrate patch) [package insert (in Japanese)] (2014) www.info.pmda.go.jp/…/650034_8219701S1025_1_09.pdf Accessed 3 May 2015

  11. Uchida E, Miyazaki T, Namiki A et al (2010) Pharmacokinetic studies of the transdermal patch containing fentanyl citrate (FT-290) in patients with cancer pain. Journal of clinical therapeutics and medicines 26:335–351

    Google Scholar 

  12. Donner B, Zenz M, Strumpf M et al (1998) Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15:168–175

    Article  CAS  PubMed  Google Scholar 

  13. Grond S, Zech D, Lehmann KA et al (1997) Transdermal fentanyl in the long term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69:191–198

    Article  CAS  PubMed  Google Scholar 

  14. Kim DY, Song HS, Ahn JS et al (2010) The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Support Care Cancer 19(2):297–301

    Article  CAS  PubMed  Google Scholar 

  15. Kokubun H, Matoba M, Hoka S et al. (2007) Relationship between serum fentanyl concentration and transdermal fentanyl dosage, and intra-individual variability in fentanyl concentration after application of fentanyl patches in patients with cancer pain. J Pharm Health Care Sci 33(3):200–205

  16. Davis AN, Dickman A, Reid C, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland et al (2009) The management of cancer-related breakthrough pain; recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338

    Article  Google Scholar 

  17. Haugen DF, Hjermstad MJ, Hagen N, European Palliative Care Research Collaborative (EPCRC) et al (2010) Assessment and classification of breakthrough cancer pain: a systematic literature review. Pain 149:476–482

    Article  PubMed  Google Scholar 

  18. National Comprehensive Cancer Network (Version 2. 2014). NCCN Clinical Practice Guidelines in Oncology, adult cancer pain. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf Accessed 3 May 2015

  19. Caraceni A, Hanks G, Kaasa S, The European Palliative Care Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC) et al (2012) Use of opioid analgesic in the treatment of the cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68

    Article  CAS  PubMed  Google Scholar 

  20. Caraceni A, Davies A, Poulain P et al (2013) Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw 11:S29–S36

    PubMed  Google Scholar 

  21. European Oncology Nursing Society guidelines (2013): breakthrough cancer pain guidelines http://www.cancernurse.eu/documents/EONSBreakthroughCancerPainGuidelines.pdf Accessed 3 May 2015

  22. Mercadante S (2011) Managing breakthrough pain. Curr Pain Headache Rep 15:244–249

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Division of Palliative Medicine, Sapporo Kiyota Hospital, 1-1-1-1 Shinei, Kiyota-ku, Sapporo, Hokkaido, 004-0831, Japan

    Kazuhiko Koike & Takuji Nishisato

  2. Division of Palliative Medicine, Higashi Sapporo Hospital, Sapporo, Hokkaido, Japan

    Tomokazu Nagasako, Iori Horiuchi, Takayuki Machino & Kunihiko Ishitani

  3. Division of Internal Medicine, Higashi Sapporo Hospital, Sapporo, Hokkaido, Japan

    Takeshi Terui, Toshiro Kusakabe, Yasuo Hirayama & Hiroyoshi Mihara

  4. Department of Anesthesiology, Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan

    Michiaki Yamakage

  5. Department of Medical Oncology and Hematology, Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan

    Junji Kato

Authors
  1. Kazuhiko Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Terui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomokazu Nagasako
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iori Horiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takayuki Machino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshiro Kusakabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Hirayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyoshi Mihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiaki Yamakage
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junji Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takuji Nishisato
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kunihiko Ishitani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhiko Koike.

Additional information

This paper was accepted as a poster at the Multinational Association on Supportive Care in Cancer (MASCC)/ISOO 2013 International Symposium in Berlin, Germany, June 27–29, 2013.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koike, K., Terui, T., Nagasako, T. et al. A new once-a-day fentanyl citrate patch (Fentos® Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. Support Care Cancer 24, 1053–1059 (2016). https://doi.org/10.1007/s00520-015-2880-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2880-9

Keywords

Search

Navigation